title: Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma.
abstract: BACKGROUND
  Both eukaryotic initiation factor 4E (eIF4E) and eIF4E binding protein 1 (4E-BP1) are involved in the malignant progression of human cancers. However, the role of eIF4E and 4E-BP1 expression as prognostic markers has not been evaluated concurrently in any human cancers.
  
  
  METHODS
  The expression of eIF4E and 4E-BP1 was semiquantitatively examined with immunohistochemical staining in 80 patients with pathological stage I invasive lung adenocarcinoma.
  
  
  RESULTS
  The 10-year survival rate was significantly lower for patients with high eIF4E expression (64.0% [n=36]) than for patients with low eIF4E expression (89.9% [n=44], P=0.024), and in patients with high eIF4E expression the 10-year survival rate was lower for patients with low 4E-BP1 expression (39.0% [n=12]) than for patients with high 4E-BP1 expression (85.2% [n=24], P=0.036). In patients with low eIF4E expression, the 10-year survival rate was lower for patients with low 4E-BP1 expression (87.6% [n=36]) than for patients with high 4E-BP1 expression (100% [n=8]), but statistical analysis was impossible because all patients with high 4E-BP1 expression were censored. Unfavorable prognostic factors for survival were age greater than 65 years (P=0.015), pathological stage IB disease (P=0.045), high eIF4E expression (P=0.008), and low 4E-BP1 expression (P=0.007).
  
  
  CONCLUSIONS
  Both eIF4E and 4E-BP1 are potential new prognostic factors for survival and stratification in patients with pathological stage I lung adenocarcinoma. The eIF4E and 4E-BP1 status may provide a basis for individualized therapy.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. nseki@med.teikyo-u.ac.jp
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Seki
authors.forename: Tasaburo
authors.initials: T
authors.lastname: Takasu
authors.forename: Shigeki
authors.initials: S
authors.lastname: Sawada
authors.forename: Masao
authors.initials: M
authors.lastname: Nakata
authors.forename: Rieko
authors.initials: R
authors.lastname: Nishimura
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Segawa
authors.forename: Reishi
authors.initials: R
authors.lastname: Shibakuki
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hanafusa
authors.forename: Kenji
authors.initials: K
authors.lastname: Eguchi
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism*; D000230:Adenocarcinoma / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018797:Cell Cycle Proteins; D018450:Disease Progression; D039561:Eukaryotic Initiation Factor-4E / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; C087000:EIF4EBP1 protein, human; D039561:Eukaryotic Initiation Factor-4E; D010750:Phosphoproteins